We ask that you declare any subsequent offer with improved terms from Boston Scientific as superior.

Elliott is extremely disappointed in your decision to accept a revised Johnson & Johnson offer that clearly fails to maximize shareholder value, and is appalled at the board's failure to stand up for the shareholders you are charged to represent.

Anything less than $71 per share from J&J should not be accepted, in our view.

It's great to be back here in Boston,

From a competitive standpoint, probably the most sensitive issues are in the Boston and Massachusetts areas. There's going to be some risk to Fleet's dominance there, but I'm not really concerned.

Boston State-house is the hub of the solar system. You couldn't pry that out of a Boston man if you had the tire of all creation straightened out for a crow-bar.